OINDP analysis and development specialist Nanopharm is now offering dissolution testing services using its proprietary UniDose aerosol collection apparatus, the company said.
UniDose allows analysts to conduct dissolution testing that is independent of the collected dose. The system deposits the entire dose at a low impaction velocity onto a high surface area filter that can then be used for testing with compendial dissolution testing methods such as paddle-over-disk.
Nanopharm Managing Director Jag Shur said, “For the first time, we have a reliable means of measuring the dissolution behavior of inhaled products. This ability has numerous applications in formulation development and optimization, as well as quality control for orally inhaled drug products (OIDPs). It is now possible to investigate the impact of raw material critical material attributes and formulation processing on dissolution, and we are continuing to evaluate the use of in vitro dissolution testing to understand its relationship with in vivo behavior.”
Nanopharm Co-Founder and Director Rob Price said, “We are pleased to be able to offer our customers a rugged, reliable approach that provides excellent discriminatory capability for characterizing the dissolution of orally inhaled drug products. Dissolution testing is increasingly recognized as an important tool for optimization of OIDP formulations and for its potential to enhance the understanding of the fate of an inhaled dose.”
Read the Nanopharm press release.
